RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…
RT @ElizSMcKenna: Now online in @CD_AACR: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven can…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @VivekSubbiah: BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined ME…
RT @CD_AACR: Just published #OnlineFirst! BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven ca…
RT @VivekSubbiah: BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined ME…
RT @VivekSubbiah: BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined ME…
RT @NicolasNassar3: The Ras-field needed a breakthrough and it is here. Impressive data. The in vivo combination treatment with trametinib…
RT @VivekSubbiah: BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined ME…
BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition https://t.co/4bSbKqrxws
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…
RT @gerlach_d: Targeting KRAS-driven cancers beyond G12C with combined SOS1::KRAS and MEK inhibition - breaking the feedback loop. Great wo…
Another option for kras driven tumors. BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition @CD_AACR @SWOG @CathyEngMD @DavendraSohal https://t.co/8Itv8uvZ6Y
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @gerlach_d: Targeting KRAS-driven cancers beyond G12C with combined SOS1::KRAS and MEK inhibition - breaking the feedback loop. Great wo…
RT @gerlach_d: Targeting KRAS-driven cancers beyond G12C with combined SOS1::KRAS and MEK inhibition - breaking the feedback loop. Great wo…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
Targeting KRAS-driven cancers beyond G12C with combined SOS1::KRAS and MEK inhibition - breaking the feedback loop. Great work with colleagues at @Boehringer Ingelheim #KRAS @CD_AACR
RT @CD_AACR: Just published #OnlineFirst! BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven ca…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @ElizSMcKenna: Now online in @CD_AACR: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven can…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…
RT @norbertkraut1: Check out our paper in @CD_AACR where we present a compelling concept to aim at a broad range of #KRAS mutant cancers ht…
RT @ElizSMcKenna: Now online in @CD_AACR: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven can…
RT @ElizSMcKenna: Now online in @CD_AACR: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven can…
RT @norbertkraut1: Check out our paper in @CD_AACR where we present a compelling concept to aim at a broad range of #KRAS mutant cancers
RT @SantiCabezas1: Mutant #KRAS: main driver in #PancreaticCancer #colorectal cancer & #NSCLC BI-3406: new oral & potent SOS1:KRAS interac…
RT @SantiCabezas1: Mutant #KRAS: main driver in #PancreaticCancer #colorectal cancer & #NSCLC BI-3406: new oral & potent SOS1:KRAS interac…
Great work Norbert and team! @norbertkraut1
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…
RT @CD_AACR: Just published #OnlineFirst! BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven ca…
RT @norbertkraut1: Check out our paper in @CD_AACR where we present a compelling concept to aim at a broad range of #KRAS mutant cancers ht…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @CD_AACR: Just published #OnlineFirst! BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven ca…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…
Now online in @CD_AACR: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined #MEK inhibition @MarcoHHofmann @norbertkraut1 @Boehringer https://t.co/F90o8aXaIo
Just published #OnlineFirst! BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined #MEK inhibition. @MarcoHHofmann @norbertkraut1 @Boehringer #DrugDevelopment https://t.co/CN675cexL1 https
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @RASopathiesnet: @Real_Dr_Kessler @D_B_McConnell Will be watching closely for application to #RASopathies Could BI-3406 be useful for…
Anti-KRAS signaling combinations beyond G12C in PDAC and CRC preclinical models. SOS1i + MEKi https://t.co/NDKdH459ze
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @NicolasNassar3: The Ras-field needed a breakthrough and it is here. Impressive data. The in vivo combination treatment with trametinib…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
Mutant #KRAS: main driver in #PancreaticCancer #colorectal cancer & #NSCLC BI-3406: new oral & potent SOS1:KRAS interaction inhibitor Potential role in #KRAS - driven cancers @_SEOM https://t.co/FE0beMYsST
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @NicolasNassar3: The Ras-field needed a breakthrough and it is here. Impressive data. The in vivo combination treatment with trametinib…
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
The Ras-field needed a breakthrough and it is here. Impressive data. The in vivo combination treatment with trametinib is very promising.
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an attractive therapeutic concept for the majority of KRAS mutant cancers, including KRAS G12D, G12V, G12C and G13D @Boehringer https://t.c
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…
RT @RASopathiesnet: @Real_Dr_Kessler @D_B_McConnell Will be watching closely for application to #RASopathies Could BI-3406 be useful for…
@Real_Dr_Kessler @D_B_McConnell Will be watching closely for application to #RASopathies Could BI-3406 be useful for NS? @Noonan_Syndrome @noonansyndrome @NoonanSyndrome1 @NoonanNet @SyndromeNoonan @Noonan2015 @NoonanSyndroom
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…
RT @Real_Dr_Kessler: Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhi…
Finally out, our SOS1 inhibitor BI-3406 publication with new impressive combination data. Combining SOS1 and MEK inhibition shows an effective therapeutic concept for a broad range of KRAS driven cancers. @MarcoHHofmann @norbertkraut1 @D_B_McConnell https